Novartis AG

SWX:NOVN Stock Report

Market Cap: CHF 173.4b

Novartis Past Earnings Performance

Past criteria checks 5/6

Novartis has been growing earnings at an average annual rate of 4.6%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 1.4% per year. Novartis's return on equity is 27.1%, and it has net margins of 23.6%.

Key information

4.6%

Earnings growth rate

6.7%

EPS growth rate

Pharmaceuticals Industry Growth16.3%
Revenue growth rate-1.4%
Return on equity27.1%
Net Margin23.6%
Next Earnings Update31 Jan 2025

Recent past performance updates

We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Nov 05
We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Recent updates

Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Dec 17
Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Nov 05
We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Investors Interested In Novartis AG's (VTX:NOVN) Earnings

Oct 21
Investors Interested In Novartis AG's (VTX:NOVN) Earnings

Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Sep 04
Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Novartis AG's (VTX:NOVN) Price In Tune With Earnings

Mar 12
Novartis AG's (VTX:NOVN) Price In Tune With Earnings

Novartis (VTX:NOVN) Has Announced A Dividend Of $3.30

Feb 20
Novartis (VTX:NOVN) Has Announced A Dividend Of $3.30

Is There An Opportunity With Novartis AG's (VTX:NOVN) 47% Undervaluation?

Jan 04
Is There An Opportunity With Novartis AG's (VTX:NOVN) 47% Undervaluation?

Revenue & Expenses Breakdown

How Novartis makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SWX:NOVN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2449,94011,76112,4797,146
30 Jun 2448,86010,08312,4378,689
31 Mar 2447,7339,10712,4388,673
31 Dec 2346,6608,56812,4899,011
30 Sep 2345,8507,24512,20610,273
30 Jun 2344,5417,06212,0518,890
31 Mar 2341,6945,97611,5228,680
31 Dec 2243,4616,04912,1438,425
30 Sep 2246,01721,04212,9248,975
30 Jun 2248,60122,47213,6068,813
31 Mar 2252,99724,18414,7989,119
31 Dec 2143,97422,90812,7568,259
30 Sep 2152,3859,80714,7219,032
30 Jun 2151,5568,98414,5228,798
31 Mar 2149,8847,95514,1368,839
31 Dec 2049,8988,07214,1978,980
30 Sep 2049,5847,10314,1288,534
30 Jun 2049,5287,21014,2588,587
31 Mar 2049,9307,45114,4758,197
31 Dec 1948,6777,14214,3699,402
30 Sep 1947,8587,23814,1148,627
30 Jun 1946,7627,07713,8268,575
31 Mar 1946,39112,69713,7368,650
31 Dec 1846,09912,79713,7178,489
30 Sep 1847,36613,55214,0848,295
30 Jun 1848,67213,75214,5018,387
31 Mar 1849,5138,00414,8128,323
31 Dec 1743,4047,49912,4687,995
30 Sep 1749,5276,68414,7138,460
30 Jun 1749,1766,54314,4358,445
31 Mar 1749,3616,36714,2788,573
31 Dec 1649,3866,71214,1118,445
30 Sep 1649,6066,80714,1108,773
30 Jun 1649,7506,67214,1738,739
31 Mar 1649,9676,72214,1418,755
31 Dec 1550,3877,01714,2478,935
30 Sep 1550,6358,41714,2418,685
30 Jun 1551,4509,69714,3438,656
31 Mar 1552,50310,53614,5528,628
31 Dec 1453,63410,65714,9939,086
30 Sep 1453,90810,19115,1228,910
30 Jun 1453,5149,23315,2318,965
31 Mar 1452,8459,09515,1899,034
31 Dec 1352,7169,19215,1898,946

Quality Earnings: NOVN has a large one-off loss of $4.9B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: NOVN's current net profit margins (23.6%) are higher than last year (15.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NOVN's earnings have grown by 4.6% per year over the past 5 years.

Accelerating Growth: NOVN's earnings growth over the past year (62.3%) exceeds its 5-year average (4.6% per year).

Earnings vs Industry: NOVN earnings growth over the past year (62.3%) exceeded the Pharmaceuticals industry 9.5%.

Return on Equity

High ROE: NOVN's Return on Equity (27.1%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 15:47
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Novartis AG is covered by 68 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamla SinghAlphaValue
John EadeArgus Research Company
Fabrizio SpagnaAxia Financial Research